Product

Cytochrome P450 (CYP) Substrates

1 clinical trial

2 indications

Indication

Ulcerative Colitis

Indication

Crohn's disease

Clinical trial

A Phase 1 Study to Evaluate the Effect of Multiple IV Infusions of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates Administered Orally in Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease

Status: Completed, Estimated PCD: 2022-10-14